Needham Reiterates Buy on Sarepta Therapeutics, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $140.
January 29, 2024 | 6:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst reaffirms Buy rating on Sarepta Therapeutics with a $140 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a respected analyst like Gil Blum from Needham, along with the maintenance of a high price target, typically instills confidence in investors and can lead to a positive short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100